[1] Wang H, Xiao M, Chen S, et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study[J].J Clin Microbiol, 2010, 50(12):3952-3959.
[2] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts;approved standard M27-A3, 3rd ed[S].Clinical and Laboratory Standards Institute, Wayne, PA, 2007.
[3] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement.M27-S3[S].Clinical and Laboratory Standards Institute, Wayne, PA, 2009.
[4] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts, fourth informational supplement.M27-S4[S].Clinical and Laboratory Standards Institute, Wayne, PA, 2012.
[5] Pfaller MA, Diekema DJ.Progress in antifungal susceptibility testing of Candida spp.by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012[J].J Clin Microbiol, 2012, 50(9):2846-2856.
[6] Mara RD, Jack F.High-throughput detection of pathogenic yeasts of the genus Trichosporon[J].J Clin Microbiol, 2004, 42(8):3696-3706.
[7] Espinel-Ingroff A, Canton E, Peman J, et al.Comparison of 24 h and 48 h voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories:results obtained with 2, 162 clinical isolates of Candida spp.and other yeasts[J].J Clin Microbiol, 2009, 47(9):2766-2771.
[8] Pfaller MA, Boyken LB, Hollis RJ, et al.Validation of 24 h fluconazole MIC readings versus the CLSI 48 h broth microdilution reference method:results from a global Candida antifungal surveillance program[J].J Clin Microbiol, 2008, 46(11):3585-3590.
[9] Pfaller MA, Boyken LB, Hollis RJ, et al.Validation of 24 h posaconazole and voriconazole MIC readings versus the CLSI 48 h broth microdilution reference method:application of epidemiological cutoff values to results from a global Candida antifungal surveillance program[J].J Clin Microbiol, 2011, 49(4):1274-1279.
[10] Food and Drug Administration.Class Ⅱ special controls guidance document:antimicrobial susceptibility test systems;guidance for industry[S].Food and Drug Administration, Washington, DC.2003.
[11] Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al.Comparison of visual 24 h and spectrophotometric 48 h MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.:a collaborative study[J].J Clin Microbiol, 2005, 43(9):4535-4540.
[12] Revankar SG, Kirkpatrick WR, McAtee RK, et al.Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method[J].J Clin Microbiol, 1998, 36(1):153-156.
[13] Rex JH, Nelson PW, Paetznick VL, et al.1998.Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis[J].Antimicrob.Agents Chemother, 1998, 42(1):129-134.
[14] Arthington-Skaggs BA, Warnock DW, Morrison CJ.Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis[J].Antimicrob Agents Chemother, 2000, 44(8):2081-2085. |